Feature | February 17, 2014

UTHealth, Memorial Hermann Perform Conscious Sedation TAVR Procedure

TAVR Heart valve repair Hybrid OR

February 17, 2014 — A team of interventional cardiologists and cardiovascular surgeons at The University of Texas Health Science Center at Houston (UTHealth) and Memorial Hermann Heart & Vascular Institute-Texas Medical Center performed Texas’ first transcatheter aortic valve replacement (TAVR) under conscious sedation using the Edwards Sapien valve.
 
Conscious sedation, in which the patient is awake and able to communicate with physicians during the procedure, is now used in many TAVR cases in Europe but is much less common in the United States.
 
The procedure circumvents an anesthesiologist inserting a breathing tube for general anesthesia. Conscious sedation can mean less recovery time, a shorter hospital stay and cost savings, physicians have reported. For traditional surgical aortic valve replacements, the hospital length of stay is five to six days. By comparison, the length of stay for TAVRs in Europe can be as low as one to two days.
 
Aortic valve stenosis, which affects approximately 300,000 Americans, is an age-related disease resulting from calcium deposits in the valve that cause it to narrow and stiffen. As it becomes harder to pump the blood to the rest of the body, the heart weakens. Patients experience fainting, chest pain, heart failure, irregular heart rhythms and cardiac arrest. Without treatment, patients usually die within two years of diagnosis.
 
This first case in Texas on Jan. 9, 2014 went so well that when patient Clifford Reed’s wife Helen arrived at the hospital a day after her husband received his new aortic valve, he was dressed and ready to go home. His doctors elected to keep him one more day for monitoring.
 
“We're not removing a tooth or sewing up a wound under conscious sedation, but doing a procedure that in the past required stopping the heart, placing the patient on cardiopulmonary bypass, removing the aortic valve, and suturing a new valve into place,” said Tom C. Nguyen, M.D. assistant professor of cardiovascular surgery at the UTHealth Medical School and cardiothoracic and vascular surgeon at the Institute. “In essence, we're doing heart surgery while the patient is partially awake.”
 
Replacing the aortic valve is traditionally done in surgery in the United States, but some patients are not candidates for surgery. TAVR, which is done via a catheter inserted into an artery, has been studied in Europe and the United States for more than a decade in frail patients who are inoperable or at high risk for open surgery.
 
Doing the procedure under conscious sedation was a natural next step.
 
“As our population ages, more and more of us are going to have these kinds of conditions and the less invasively we can manage them, the better these patients will hopefully be in the future,” said Prakash Balan, M.D., assistant professor of interventional cardiology at the UTHealth Medical School and part of the Institute team performing the procedure.
 
“With this procedure, we were able to put in a new valve while the patient was awake in about an hour and 10 minutes, so that’s a huge advance,” said Richard W. Smalling, M.D., Ph.D., the James D. Woods Distinguished Chair in Cardiovascular Medicine and director of interventional cardiovascular medicine in the Division of Cardiology at UTHealth and the Institute.
 
As he was wheeled out of the catheter lab, Clifford Reed, who is 87, told Nguyen and Balan that he was “feeling a lot better now.”
 
His wife noticed an immediate change.
 
“Before he used to be light-headed and he wasn’t sure on his feet. He also had a lot of chest pain,” Helen Reed said. “Now his chest isn’t hurting and he’s doing great. It’s a miracle.”
 
For more information: www.uth.edu
 

Related Content

News | Heart Valve Technology

May 19, 2022 — A study of 1-year outcomes in the largest cohort to date of Harmony transcatheter pulmonary valve (TPV) ...

Home May 19, 2022
Home
News | Heart Valve Technology
May 5, 2022 – Foldax, Inc. has announced that the first patients have been enrolled in the Drugs Controller General of ...
Home May 05, 2022
Home
News | Heart Valve Technology

April 27, 2022 — The U.S. Food and Drug Administration (FDA) has issued a Class I recall for the Medtronic Harmony ...

Home April 27, 2022
Home
News | Heart Valve Technology
March 2, 2022 – An international study led by a researcher from Tel Aviv University offers a novel technology that can ...
Home March 02, 2022
Home
News | Heart Valve Technology
February 28, 2022 - Foldax, Inc. has announced the presentation of results from the first animal study of its ...
Home February 28, 2022
Home
News | Heart Valve Technology
February 14, 2022 — SMT (Sahajanand Medical Technologies Limited) has announced the publication of Hydra Transcatheter ...
Home February 14, 2022
Home
News | Heart Valve Technology

December 13, 2021 - Foldax Inc. announced that the Drugs Controller General of India (DCGI), India’s regulatory body for ...

Home December 13, 2021
Home
News | Heart Valve Technology

November 9, 2021 — New five-year data from the SURTAVI trial found that there was no difference in all-cause mortality ...

Home November 09, 2021
Home
Feature | Heart Valve Technology

July 8, 2021 – Xeltis announced it started the first pivotal trial for a synthetic polymer restorative pulmonary valve ...

Home July 08, 2021
Home
News | Heart Valve Technology

June 2, 2021 – LivaNova announced June 1 it successfully completed the initial closing of the divestiture of its heart ...

Home June 02, 2021
Home
Subscribe Now